FDA Approves Eli Lilly Once Weekly Insulin Onswik

Business27 days ago

Patients with type 2 diabetes can reduce their total injections by more than 300 per year using a new basal insulin treatment from Eli Lilly. The US Food and Drug Administration approved the drug, Onswik, on Thursday for adults with the condition, allowing them to replace daily long acting shots with a single dose every seven days.

The medication is expected to become available in the U.S. in the coming months. Lilly stated that Onswik serves as an alternative to daily basal insulin for adults who need to manage their blood glucose levels.

Mapped to your portfolio

Possible scenarios

40%Rapid US Uptake+0.1%
25%Managed Access Limits+0.0%
20%Safety Monitoring Overhang-0.0%

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.

Looking for more context or analysis?

Tilt chat provides reliable, tailored insights, alerts, and automations.

FDA Approves Eli Lilly Once Weekly Insulin Onswik

In this story

Eli Lilly and Company United States Food and Drug Administration United States

$LLYEli Lilly & Co.

Portfolio

SPY
State Street SPDR S&P 500 ETF Trust
100%

Portfolio

SPY
State Street SPDR S&P 500 ETF Trust
100%

Mapped to your portfolio

Possible scenarios

40%Rapid US Uptake+0.1%
25%Managed Access Limits+0.0%
20%Safety Monitoring Overhang-0.0%

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.